Global Cancer News

AACR Virtual Annual Meeting I presents new data on cancer biology, treatment, screening, risk reduction

Brief points covered in the America Association for Cancer Research (AACR) Virtual Annual Meeting I held on April 27-28th:

-Treating BRAF-Positive Melanoma by adding checkpoint inhibitor Tecentriq (atezolizumab) to a combination of two targeted drugs Zelboraf (vemurafenib) and Cotellic (cobimetinib)

-PARP Inhibitor (targeted drugs that inhibit DNA damage repair) are approved by the FDA for the treatment of ovarian, breast, and pancreatic cancers.

-MET-inhibitor shows efficacy for non-small cell lung cancer and related brain metastases

-DETECT-A as the first to test a multicancer screening blood test in health patients and use results to guide further care

-COVID-19 and Cancer

For more information, see: